期刊文献+

PTEN和mTOR在食管鳞癌组织中的表达及意义 被引量:3

Expression of PTEN and m TOR in esophageal squamous carcinoma tissues and their significance
下载PDF
导出
摘要 目的观察食管鳞癌组织中PTEN与m TOR的表达,探讨其与临床病理特征的关系。方法应用免疫组化染色检测148例食管鳞癌组织、癌旁组织及其正常食管组织中PTEN和m TOR表达,分析其与常见临床病理特征的关系。结果PTEN在癌组织中阳性表达率为43.9%,癌旁组织为67.6%,而正常组织为93.2%,食管癌组织中PTEN表达率均低于癌旁组织及正常食管黏膜组织,差异有统计学意义(P<0.05);m TOR在癌组织中阳性表达率为85.8%,癌旁组织为35.1%,而正常组织为3.4%,食管癌组织中m TOR表达明显高于癌旁组织及正常食管组织,差异有统计学意义(P<0.05)。PTEN的表达与m TOR的表达强度呈负相关(P<0.05)。m TOR表达与性别、年龄、肿瘤长度差异无统计学意义(P>0.05),而与肿瘤浸润深度、肿瘤分化程度以及有无淋巴结转移上差异无统计学意义(P<0.05)。结论 m TOR信号通路的激活与PTEN的抑制,可能在食管鳞癌的发生发展中起重要的作用,PTEN低表达与m TOR高表达与肿瘤恶性程度有关,两者联合检测可能有助于预后的判断。 Objective Observe the expression of PTEN and m TOR in esophageal squamous carcinoma tissues and explore their relationship with the pathological types. Methods The expressions of PTEN and m TOR were detected in 148 cases of esophageal squamous carcinoma, counterpart para-carcinoma and normal tissues by immunohistochemistry, analyzing their relevance with the clinical pathological features. Results There was significant differencein PTENamong esophageal squamous carcinoma tissues(43.9%), counterpart para-carcinoma tissues(67.6%), and normal tissues(93.2%), decreased in esophageal squamous carcinoma(P 〈0.05); while the expression of m TOR among theesophageal squamous carcinoma tissues(85.8%),counterpart para-carcinoma tissues(35.1%), and normal tissues(3.4%), with statistical significance(P〈0.05), and PTEN was strong negative correlation with m TOR. Further, there is no statistically significant difference between m TOR and sex, age and tumor length(P 〉0.05), however, Statistical analysis showed a significant difference between m TOR andtumor infiltration depth degree, tumor differentiation and presence of lymph node metastasis(P〈0.05) respectively. Conclusions m TOR and PTEN may play an important role in esophageal squamous carcinoma, their joint detection may contribute to evaluate prognosis.
出处 《解剖学研究》 CAS 2014年第6期447-450,共4页 Anatomy Research
基金 广东省科技计划项目(2011B080701095)
关键词 食管鳞状细胞癌 雷帕霉素靶蛋白 PTEN抑癌基因 esophageal squamous carcinoma m TOR PTEN
  • 相关文献

参考文献13

  • 1Hongo M,Nagasaki Y,Shoji T.Epidemiology of esophageal cancer:Orient to Occident.Effects of chronology,geography and ethnicity.J Gastroenterol Hepatol,2009,24(5):729-735.
  • 2Dillon RL,White DE,Muller WJ.The phosphatidyl inositol 3-kinase signaling network:implications for human breast cancer.Oncogene,2007,26(9):1338-1345.
  • 3Li H,Zeng J,Shen K.PI3K/AKT/m TOR signaling pathway as a therapeutic target for ovarian cancer.Arch Gynecol Obstet,2014.
  • 4Wang YY,Lv YF,Lu L,et al.Oridonin inhibits m TOR signaling and the growth of lung cancer tumors.Anticancer Drugs,2014.
  • 5Li J,Yen C,Liaw D,et al.PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast,and prostate cancer.Science,1997,275(5308):1943-1947.
  • 6陈廷玉,卢春凤,苗智,邵文武,张晓波.宫颈癌PCNA和PTEN的表达与癌细胞增殖及淋巴结转移的关系[J].解剖学研究,2010,32(1):17-20. 被引量:7
  • 7Xu LF,Wu ZP,Chen Y,et al.Micro RNA-21(mi R-21)Regulates cellular proliferation,invasion,migration,and apoptosis by targeting PTEN,RECK and Bcl-2 in lung squamous carcinoma,gejiu city,China.PLo S One,2014,9 (8):e103698.
  • 8Lin HJ,Hsieh FC,Song H,et al.Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer.Br J Cancer,2005,93(12):1372-1381.
  • 9Tsurutani J,West KA,Sayyah J,et al.Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.Cancer Res,2005,65(18):8423-8432.
  • 10Takeuchi H,Kondo Y,Fujiwara K,et al.Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.Cancer Res,2005,65(8):3336-3346.

二级参考文献14

  • 1Aziz SA, Pervez S, Khan SM, et al. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast. J Coil Physicians Surg Pak, 2005,15 (4) : 225-229.
  • 2Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology, 2005, 68 (4-6) : 398-404.
  • 3Takei Y, Saga Y, Mizukami H, et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther, 2008,7(3) :704 -711.
  • 4Tomioka A, Tanaka M, De Velasco MA, et al. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther, 2008,7(7) : 1864-1870.
  • 5Dellas A, Jundt G, Sartorius G, et al. Combined PTEN and p27kip1 Protein Expression Patterns Are Associated with Obesity and Prognosis in Endometrial Carcinomas. Clin Cancer Res, 2009, 15(7) :2456-2462.
  • 6Yaginuma Y, Yamashita T, Ishiya T, et al. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog, 2000,27 (2) : 110- 116.
  • 7Harima Y, Sawada S, Nagata K, et al. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol, 2001,18(3) :493-498.
  • 8Cheung TH, Lo KW, Yim SF, et al. Epigenetic and genetic ahemation of PTEN in cervical neoplasm. Gynecol Oncol, 2004,93 (3) : 621-627.
  • 9Lee JS, Choi YD, Lee JH, et al. Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J Surg Oncol, 2006,93 (3) : 233-240.
  • 10Kumaraguruparan R, Prathiba D, Nagini S. Of humans and canines: Immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours. Res Vet Sci, 2006,81(12) :218-224.

共引文献6

同被引文献31

  • 1温晓燕,张维东.乳腺癌癌前病变的病理学研究进展[J].实用癌症杂志,2006,21(4):437-439. 被引量:4
  • 2Maiques 0, Cuevas D, Garcia Dios DA et al. FISH analy- sis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA. Histopathology, 2014,65(3):371- 388.
  • 3Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11 (2) : 121-128.
  • 4Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or car- boplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009,361 (10) : 947-957.
  • 5Rosell R, Carcereny E, Gervais R. Erlotinib versus stan- dard chemotherapy as first-line treatment for European pa- tients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-346.
  • 6Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and in- ferior responses to tyrosine kinase inhibitors in cancer. Nat Med, 2012,18(4) : 521-528.
  • 7Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib ther- apy in non-small-cell lung cancer patients. Ann Oncol, 2009,20(2) :298-304.
  • 8Morgillo F, Kim WY, Kim ES, et al., Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res, 2007,13 (9) : 2795-803.
  • 9Sos ML, Koker M, Weir BA. PTEN loss contributes to er- lotinib resistance in EGFR-mutant lung cancer by activa- tion of Akt and EGFR. Cancer Res, 2009,69(8):3256- 3261.
  • 10Marsit C J, Zheng S, Aldape K, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 2005,36(7) :768-776.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部